- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 263/32 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Patent holdings for IPC class C07D 263/32
Total number of patents in this class: 585
10-year publication summary
|
46
|
43
|
31
|
46
|
45
|
43
|
43
|
34
|
28
|
13
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Otsuka Pharmaceutical Co., Ltd. | 1499 |
17 |
| Takeda Pharmaceutical Company Limited | 2712 |
12 |
| Bristol-myers Squibb Company | 4879 |
10 |
| Merck Sharp & Dohme LLC | 3751 |
10 |
| Pro Farm Group, Inc. | 119 |
10 |
| Abbvie Inc. | 1800 |
8 |
| Canopy Growth Corporation | 219 |
8 |
| The Scripps Research Institute | 1347 |
8 |
| Shionogi & Co., Ltd. | 860 |
8 |
| H. Lundbeck A/S | 1234 |
8 |
| F. Hoffmann-La Roche AG | 7934 |
7 |
| Hoffmann-La Roche Inc. | 3404 |
7 |
| Argenta Discovery Ltd. | 46 |
7 |
| Calico Life Sciences LLC | 96 |
7 |
| Toray Industries, Inc. | 6930 |
6 |
| Arcus Biosciences, Inc. | 137 |
6 |
| Oncternal Therapeutics, Inc. | 35 |
6 |
| Astellas Pharma Inc. | 1088 |
5 |
| Kissei Pharmaceutical Co., Ltd. | 187 |
5 |
| Sanford Burnham Prebys Medical Discovery Institute | 297 |
5 |
| Other owners | 425 |